Introduction COVID-19 vaccines have been highly effective in reducing morbidity and
mortality during the pandemic. While primary series vaccination rates are generally high in …

Introduction Since its emergence, there have been huge efforts to design vaccines against
coronavirus disease 2019 (COVID-19) to inhibit its interpersonal spread. Global vaccine …

We investigated thrombocytopenic, thromboembolic and hemorrhagic events following a
second dose of ChAdOx1 and BNT162b2 using a self-controlled case series analysis. We …

Objective To quantify the comparative risk of thrombosis with thrombocytopenia syndrome or
thromboembolic events associated with use of adenovirus based covid-19 vaccines versus …

Background Post-authorisation vaccine safety surveillance is well established for reporting
common adverse events of interest (AEIs) following influenza vaccines, but not for COVID-19 …

A common framework for health data governance standards | Nature Medicine Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …

Background The two-dose BNT162b2 (Pfizer-BioNTech) vaccine has demonstrated high
efficacy against COVID-19 disease in clinical trials of children and young people (CYP) …

Data-enabled responses to pandemics: policy lessons from COVID-19 | Nature Medicine Skip to
main content Thank you for visiting nature.com. You are using a browser version with limited …

Abstract Background The CVD-COVID-UK consortium was formed to understand the
relationship between COVID-19 and cardiovascular diseases through analyses of …

On March 11, 2020, WHO declared the outbreak of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) a global pandemic. Now, almost 2 years on, COVID-19 …